Cullinan Therapeutics develops bispecific T cell engager therapies for autoimmune diseases and cancer. CGEM reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for CGEM are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in CGEM in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CGEM is in one of them and how their past CGEM trades turned out.
Cullinan Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, that develops drug candidates for autoimmune diseases and cancer. Its main programs are bispecific T cell engagers, a type of antibody therapy designed to direct immune T cells against target cells. The company is testing these candidates in clinical trials for lupus, rheumatoid arthritis, Sjögren's disease, and acute myeloid leukemia, and it also works with a partner on an oral lung cancer treatment. Its target patients are people living with these conditions.
